Navigation Links
AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Date:7/31/2013

SKOKIE, Ill., July 31, 2013 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation and modulation agents for a variety of diseases, including applications in oncology, dermatology, neurology, and for immune disorders, has closed the second tranche of its Series B financing.  The investment adds to the initial Series B round completed in December 2011.  Investors in the Series B round include AbbVie, Inc.  Other key individual investors in the round include Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Boon Hwee Koh, Director of Agilent Technologies and former Chairman of Singapore Airlines, and Craig Mundie, Chief Research and Strategy Officer of Microsoft.  Terms of the investment were not disclosed.

"It's fantastic to have so many investors from the original consortium come back for this follow-on investment round," said Van Crocker, Vice President of Commercial Development for AuraSense Therapeutics.  "This financing shows the faith our investors have in the technology, the team and our progress to date.  We look forward to taking our first SNA constructs through the preclinical development phase."

Schiff Hardin LLP served as deal counsel to AuraSense Therapeutics for the investment transaction.

About AuraSense Therapeutics, LLC

AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton of Northwestern University.  Headquartered in Skokie, Illinois, the Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates.  Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases.  The Company's SNA technology overcomes the most difficult obstacles to gene regulation:  genetic targeting with safe and effective in vivo performance.  For additional information about the company, please visit www.aurasensetherapeutics.com.


'/>"/>
SOURCE AuraSense Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
2. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
3. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
4. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
5. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
6. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
9. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
10. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
11. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):